BD Completes Bard Acquisition

 

January 2, 2018—BD (Becton, Dickinson and Company) recently announced it has completed the acquisition of CR Bard, Inc. The combined company, which will have approximately $16 billion in revenue, integrates Bard's 16,000 employees with BD's 65,000 employees.

A definitive agreement for the transaction was first announced in April 2017.

Bard Peripheral Vascular, a division of CR Bard, manufactures and markets devices for the treatment of peripheral and coronary artery diseases. For coronary interventions, Bard's portfolio includes the Bard Snare retrieval kit, the Porter hydrophilic guidewire for treatment of chronic total occlusions, and the True, True Flow, Vida BAV, and Vida PTV valvuloplasty balloon catheters. Peripheral devices include the Lutonix 035 paclitaxel-coated balloon and the Atlas, Conquest, Dorado, and Ultraverse lines of percutaneous transluminal angioplasty balloons.

With completion of the acquisition, Bard became a wholly owned subsidiary of BD.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.